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Background/aim: There are different modalities for management of infantile hemangiomas (IHs). In this report, our aim is to evaluate
whether intralesional corticosteroid treatment is associated with systemic side effects and whether this is an effective treatment modality
for IH.
Materials and methods: Six children treated with intralesional corticosteroids for problematic hemangiomas were included in the
study. Clinical characteristics, response to treatment, weight, height, blood pressure, morning serum cortisol, and adrenocorticotropic
hormone levels were recorded.
Results: Each child received intralesional triamcinolone at a dose of 2 mg/kg for 2–5 injections at monthly intervals. Subjects
were followed for 1 year. All patients had adrenal suppression following the second or third triamcinolone injections. Five patients
demonstrated partial response and one demonstrated no response.
Conclusion: Intralesional steroid injection may effectively induce the resolution of hemangiomas, but all the patients in our group had
adrenal suppression after treatment. The use of intralesional steroid therapy is not a superior treatment option for hemangiomas. It also
has side effects comparable to systemic steroids.
Key words: Hemangioma, intralesional, corticosteroid, adrenal suppression

1. Introduction
Infantile hemangiomas (IHs), the most common benign
tumor of infancy, occur in about 10% of infants. Although
they occur in 8%–12% of newborns, this prevalence rate
can reach 22% in premature babies. There is marked
predominance of female cases. Classically, IHs appear
shortly after birth as a light pink telangiectatic macule.
They have a natural history of rapid growth during
the first year of life, followed by a slow spontaneous
regression phase after 12–18 months. Approximately 70%
of hemangiomas regress completely by the age of 7. IHs
that do not regress by the sixth year of life will develop
residual abnormalities, the most common of which are
telangiectasia, atrophic wrinkling, yellowish discoloration,
redundant skin, scarring, and alopecia (1,2).
The goals in the management of the IH are to prevent
or reverse complications like ulceration or scarring and
permanent disfigurement and to minimize psychosocial
stress for parents. Since incidence of spontaneous
resolution in hemangiomas is very high, close clinical
follow-up and observation are adequate in most cases (2).
* Correspondence: sunaemir@yahoo.com

There are different modalities for management
of IHs. Systemic corticosteroids were the preferred
treatment in severe cases until recently. Their principal
effect is to stop the growth and induce regression of the
lesion, possibly by inhibiting angiogenesis and inducing
apoptosis. Steroids must be used with caution secondary
to the risk of systemic side effects, such as growth
disturbance and immune suppression. Since systemic
steroids have potentially serious side effects, intralesional
corticosteroid injection has been recommended by
certain authors because of reported rapid onset of
action and associated safety (3). Since Léauté-Labrèze
et al. reported the incidental finding that IHs regress in
children treated with propranolol, a nonselective betablocker for cardiac and renal conditions, this medication
has been widely used to treat IHs (4). Nevertheless, there
is still controversy regarding the effectiveness and adverse
effects associated with this treatment. Use of propranolol
is also difficult because of compliance and side effects in
some cases (5,6).
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Here we report our experience with 6 patients with
IHs treated with intralesional corticosteroid injection. We
evaluated whether intralesional corticosteroid treatment is
associated with systemic side effects and whether this is an
effective treatment modality for IH.

adrenal suppression. Patients were followed monthly
for 1 year. The size of the IH was measured at each visit.
Complete response was defined as a reduction of over 75%
in size, consistency, or color of the lesion. Partial response
was defined as a reduction of 50%–75% with respect to
these same parameters and no response was defined as no
change following treatment.

2. Materials and methods
Six children treated with intralesional corticosteroid for
hemangiomas at our pediatric oncology department were
retrospectively evaluated. After physical examination,
superficial and abdominal ultrasonography was
performed in all patients for exclusion of other vascular
malformations. Indications for intralesional corticosteroid
injections were cosmetic disfigurement in 2 patients,
bleeding in 3 patients, and ulceration in 1 patient. Prior
to treatment with intralesional corticosteroids, response
rate and compliance with oral propranolol were poor in
all 6 patients. Propranolol had been initiated at the daily
dose of 1 mg/kg in two divided doses and increased to 2
mg/kg on day 7 for 2 months. Propranolol was stopped in
one child because of bronchial hyperreactivity and in two
children because of the poor compliance of the parents.
No significant changes in size or color were observed in
the remaining patients after 2 months.
This study was approved by the hospital’s ethics
committee. Informed consent was obtained from the
parents. All children received intralesional triamcinolone
at a dose of 2 mg/kg for 2–5 injections at monthly intervals.
The injections were given by a 22-gauge needle directly
into the IH. Weight, height, blood pressure, morning
serum cortisol, adrenocorticotropic hormone (ACTH),
fasting serum glucose, and serum electrolytes were
measured before each injection and at 4-week intervals
thereafter to evaluate corticosteroid side effects. Patients
with an early morning serum cortisol concentration of
<5 ng/mL 4 weeks after injection were considered to have

3. Results
We evaluated 6 girls with median age of 7 months (range:
5–18 months) treated with intralesional corticosteroid
injections. Basal height and weight percentiles and serum
ACTH and cortisol levels were within normal ranges
in all patients. The hemangiomas were located on the
trunk in 4 cases and on the head in 2 cases. The number
of injections varied from 2 to 5 injections. One of the
patients received 5, two received 4, one received 3, and
two received 2 injections of intralesional triamcinolone.
Pretreatment cortisol concentrations were normal in all
6 patients, indicating normal adrenal function, before
steroid treatment. All patients had adrenal suppression
following the second or third triamcinolone injections.
Intralesional triamcinolone injections were discontinued
when a patient developed abnormal serum cortisol.
Patients’ demographics, the location and size of the IH,
treatment response, adrenal suppression, and recovery
times are shown in Table 1. Five patients demonstrated
partial response and one demonstrated no response.
Height and weight percentiles did not differ after the
therapy. None of the patients developed growth delay or
cushingoid phenotype. Blood glucose, blood pressure,
and serum electrolytes were within normal ranges during
the therapy. The time from first corticosteroid injection
to adrenal recovery ranged from 4 to 9 months. Patients’
serum ACTH and cortisol levels at diagnosis and followup are shown in Table 2.

Table 1. Patients’ demographics, localization and size of the lesion, treatment response, adrenal suppression, and recovery times.

Patient

Age at first
injection (months)

Site and size of the lesion

Number of
injections

Treatment
response

Time of adrenal
suppression
(months)

Recovery
time of adrenal
suppression (months)

1

5

Anterior chest wall, 2.5 × 2.5 cm

4

Partial

5

9

2

7

Frontal area, 2 × 2.5 cm

2

Partial

4

7

3

18

Left shoulder, 3.5 × 3.5 cm

3

No

6

9

4

17

Anterior chest wall, 3.5 × 3.7 cm

5

Partial

5

9

5

18

Anterior chest wall, 3.8 × 4.8 cm

4

Partial

3

9

6

5

Nose, 3 × 2.5 cm

2

Partial

2

4

336

EMİR et al. / Turk J Med Sci
Table 2. Patients’ serum ACTH and cortisol levels at diagnosis and during follow-up.

Patient

Cortisol,
month 0
(ng/mL)

ACTH,
month 0
(pg/mL)

Cortisol,
month 3
(ng/mL)

ACTH,
month 3
(pg/mL)

Cortisol,
month 6
(ng/mL)

ACTH,
month 6
(pg/mL)

Cortisol,
month 9
(ng/mL)

ACTH,
month 9
(pg/mL)

1

5.7

10.1

5.2

11.2

3.4

<1

6.1

9.2

2

7.1

9.3

5.3

8.1

3

<1

6.2

8.2

3

18.7

12.3

6.3

10.2

1

<1

5.9

8.1

4

5

7.8

1.2

<1

3

7.1

8

10.1

5

5.6

8.1

3.8

<1

2

5.4

7.9

9

6

5.5

9.8

4

2

5.2

8

5.6

9.1

Reference values for serum ACTH levels: 6.2–60 pg/mL.
Reference values for serum cortisol levels: 5–29 ng/mL.

4. Discussion
Although IHs are benign and self-limited lesions in
children, the duration of the spontaneous regression
cannot be estimated and this time period may result
in psychosocial stress for parents. Different treatment
modalities may be used for IH. Classical management
strategy in IH is observation with regular follow-up. The
decision to employ active therapy must be determined by
the individual features of the IH, such as rapidity of growth
and anatomical location (7).
The most commonly used therapy for hemangiomas
was systemic corticosteroids until recent years. Many
clinicians now hesitate due to their various potential
side effects and the long duration of the treatment.
Currently, propranolol has been shown to inhibit vascular
proliferation of capillary hemangioma (4,8). It has been
accepted as an effective treatment option for hemangiomas
and used as first-line treatment (9–12).
On the other hand, various complications have been
also reported with systemic propranolol treatment.
Side effects profiles can include hypersomnolence,
reflux, bronchospasm, hypotension, hypoglycemia, and
hyperkalemia. In addition, response rate and proper
oral use of propranolol can be poor in some children
(13,14). When propranolol usage failed, we decided to use
intralesional steroid in our cases.
Local steroid injection for treatment of hemangiomas
was first described by Kushner in 1982 and has been
used because of fewer side effects compared with
systemic corticosteroids (15). Several authors reported
successful treatment of hemangiomas with intralesional
steroid therapy. Gangopadhyay et al. reported that

overall response rate was 88.6% with administration of
intralesional triamcinolone and no side effects occurred
(16). Another two studies also showed response rates of
up to 90% with intralesional corticosteroid treatment
(17,18). Similarly, we demonstrated partial response in
83.3% of patients.
On the other hand, adrenal suppression and atrophic
or depigmented skin changes have been reported to
occur after intralesional corticosteroid injections (19).
Morkane et al. reported that 13 of 15 infants had adrenal
suppression 4 weeks after intralesional corticosteroid
therapy. They also demonstrated a significant slowing
in weight gain following intralesional steroid injections.
The time from first injection to basal adrenal recovery
was 4 to 65 weeks (20). Goyal et al. speculated that initial
release of glucocorticoids into the circulation led to acute
adrenal suppression (21). In our study all of the patients
had adrenal suppression following the second or third
corticosteroid injection and adrenal recovery took from 4
to 9 months from the first injection. However, a significant
slowing in weight gain and cushingoid phenotype were not
observed in our group. In addition, no patient developed
atrophic or depigmented skin changes due to intralesional
steroid application.
In conclusion, our study showed that intralesional
steroid injection may be slightly effective for inducing the
resolution of rapid growth of hemangiomas in children.
However, all the patients in our group had adrenal
suppression after intralesional steroid injections. The use
of intralesional steroid therapy is not a superior treatment
option for hemangiomas. It also has side effects like
systemic steroids.
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